WebsiteClosers®, in partnership with Fortunet, presents an established Medical Products CPG Company generating approximately $145M in LTM sales and $22.3M in Adjusted EBITDA. Founded in 2006, the Company operates two proprietary brands across FDA-cleared medical devices, healthcare consumables, patient-care essentials, and therapeutic support products. Its integrated infrastructure encompasses product development, regulatory compliance, international manufacturing, institutional supply, and multi-channel distribution.
Business Model
The portfolio includes approximately 270 active SKUs spanning medical examination gloves, adult care wipes, under pads, protective supplies, and therapeutic positioning products. Select products hold FDA 510(k) clearances, complemented by applicable Health Canada approvals and UKCA/CE markings.
Approximately 30% of revenue is B2B, serving healthcare providers, senior-care facilities, national distributors and commercial institutions. Established wholesale and private-label relationships include major pharmacy and medical supply networks, providing recurring institutional purchasing without dedicated advertising expenditure.
Market Leadership & Customer Economics
The Company holds #1 positions in three major product segments, commanding 24% market share in nitrile glove cases, 32% in adult wipes, and 22% in wedge pillows within their respective online categories. Its brands have accumulated 140,000+ customer reviews averaging 4.5 stars and maintain 10%+ purchase share across more than 3,000 specialized search terms.
Recurring demand is a defining characteristic. The Company has 71,000+ active subscriptions, up 170% since 2024, with 87% retention after 30 days and 71% after 90 days. Established subscribers generate 3.1 times the purchasing value of one-time customers.
Approximately 413,000 repeat customers generated 48.3% of 2025 sales, despite the absence of formal email, SMS, or loyalty marketing programs. Conversion rates increased from 17% to 26% between 2023 and 2025, while product refund rates declined from 3.5% to 2.2%.
Operations & Infrastructure
An experienced 24-person organization manages product commercialization, procurement, digital marketing, logistics, and quality assurance. More than 25 suppliers across six countries support industrial-scale sourcing, with approximately 700 containers imported during 2025.
Manufacturing diversification has shifted 53% of production outside China, including 90% of leading glove products. Medical items undergo independent third-party inspections supported by established quality control procedures.
The Company maintains trademark protection across eight international markets, two patents, proprietary advertising technology, and established domestic fulfillment infrastructure
Growth Opportunities
• Expand institutional healthcare distribution, government procurement and specialized medical supply kitting programs.
• Commercialize 11+ pipeline products and expand into adjacent medical consumables and patient-care categories.
• Deepen national pharmacy, medical distributor, wholesale, and private-label relationships.
• Accelerate Walmart, Canadian, and UK/European distribution and selectively enter additional international markets.
• Build direct-to-consumer distribution and lifecycle marketing capabilities across approximately 1.9 million annual customers.
• Capture additional operating efficiencies through packaging optimization, procurement leverage, and supply chain integration.
Business Broker Takeaways
1. Category Leadership. #1 positions across three major product segments, supported by FDA-cleared products, intellectual property, and established brand recognition.
2. Recurring Demand. 71,000+ subscriptions, 48.3% repeat-customer revenue and approximately 30% institutional and commercial sales.
3. Strategic Infrastructure. Diversified international sourcing, national healthcare distribution relationships, and scalable operating capabilities.
Summary
The acquisition provides an established Medical Products platform with significant category share, recurring healthcare demand, institutional distribution, regulatory credentials and proprietary operating infrastructure. Strategic buyers and financial sponsors have multiple opportunities to accelerate growth through national healthcare distribution, product portfolio expansion, international markets, and operational integration.
